These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10772443)

  • 1. Efficacy of cryopreserved recombinant alteplase for declotting thrombosed central catheters.
    Isaac BF
    Ann Pharmacother; 2000 Apr; 34(4):533-4. PubMed ID: 10772443
    [No Abstract]   [Full Text] [Related]  

  • 2. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
    Haire WD; Atkinson JB; Stephens LC; Kotulak GD
    Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
    Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
    J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
    Jacobs BR; Haygood M; Hingl J
    J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
    Ng R; Li X; Tu T; Semba CP
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters.
    Atkinson JB; Bagnall HA; Gomperts E
    JPEN J Parenter Enteral Nutr; 1990; 14(3):310-1. PubMed ID: 2112648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
    Cesaro S; Paris M; Corrò R; Svaluto G; Zanon GF; Gamba P; Milanesi O; Messina C; Zanesco L
    Support Care Cancer; 2002 Apr; 10(3):253-5. PubMed ID: 11904791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters.
    Castner D
    Nephrol Nurs J; 2001 Aug; 28(4):403-4, 407-10. PubMed ID: 12143462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolysis of blocked hemodialysis catheter using recombinant tissue-type plasminogen activator.
    Hannah A; Buttimore AL
    Nephron; 1991; 59(3):517-8. PubMed ID: 1758554
    [No Abstract]   [Full Text] [Related]  

  • 14. Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C.
    Wiernikowski JT; Crowther M; Clase CM; Ingram A; Andrew M; Chan AK
    Lancet; 2000 Jun; 355(9222):2221-2. PubMed ID: 10881901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using alteplase to clear occlusions.
    Moureau N
    Nursing; 2002 Jan; 32(1):73. PubMed ID: 12926500
    [No Abstract]   [Full Text] [Related]  

  • 16. Lytic therapy in central venous catheters for hemodialysis.
    McFarland HF; Dinwiddie L; Ferrell J; Forloines-Lynn S
    Nephrol Nurs J; 2002 Aug; 29(4):355-60; quiz 361-2. PubMed ID: 12224368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
    Little MA; Walshe JJ
    Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
    Jonker MA; Osterby KR; Vermeulen LC; Kleppin SM; Kudsk KA
    JPEN J Parenter Enteral Nutr; 2010; 34(4):444-9. PubMed ID: 20631392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local thrombolysis with recombinant tissue plasminogen activator for thrombosed vascular access in hemodialysis patients.
    Vlassopoulos D; Logothetis E; Arvanitis D; Noussias C; Magana P; Katopodis K; Hadjiconstantinou V
    Clin Nephrol; 1996 Jul; 46(1):77-8. PubMed ID: 8832159
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
    Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
    Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.